Market Closed -
OTC Markets
02:35:44 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
0.1298
USD
|
+0.49%
|
|
-2.04%
|
-7.29%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
79.15
|
81.44
|
60.5
|
61.56
|
35.34
|
29.4
|
Enterprise Value (EV)
1 |
75.96
|
83.14
|
63.4
|
60.75
|
29.59
|
25.46
|
P/E ratio
|
-9.59
x
|
-8.54
x
|
-26.8
x
|
11.3
x
|
4.73
x
|
9.34
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
10.6
x
|
10.8
x
|
3.36
x
|
2.43
x
|
1.1
x
|
0.86
x
|
EV / Revenue
|
10.2
x
|
11
x
|
3.52
x
|
2.39
x
|
0.92
x
|
0.75
x
|
EV / EBITDA
|
-9.41
x
|
-10.5
x
|
-64.7
x
|
17.8
x
|
4.72
x
|
4.87
x
|
EV / FCF
|
-47.7
x
|
-38
x
|
-31.4
x
|
41.5
x
|
7.64
x
|
-6.29
x
|
FCF Yield
|
-2.1%
|
-2.63%
|
-3.19%
|
2.41%
|
13.1%
|
-15.9%
|
Price to Book
|
17.6
x
|
-32.6
x
|
-18.6
x
|
3.81
x
|
1.4
x
|
1.02
x
|
Nbr of stocks (in thousands)
|
791,517
|
822,605
|
840,304
|
1,009,177
|
1,011,282
|
1,013,915
|
Reference price
2 |
0.1000
|
0.0990
|
0.0720
|
0.0610
|
0.0350
|
0.0290
|
Announcement Date
|
6/14/18
|
6/21/19
|
6/30/20
|
6/14/21
|
6/29/22
|
6/29/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
7.459
|
7.569
|
17.99
|
25.38
|
32.26
|
34.16
|
EBITDA
1 |
-8.069
|
-7.916
|
-0.9798
|
3.404
|
6.266
|
5.232
|
EBIT
1 |
-9.051
|
-9.159
|
-2.285
|
2.105
|
5.071
|
3.969
|
Operating Margin
|
-121.35%
|
-121.01%
|
-12.7%
|
8.29%
|
15.72%
|
11.62%
|
Earnings before Tax (EBT)
1 |
-3.673
|
-9.279
|
-2.238
|
4.145
|
7.162
|
3.986
|
Net income
1 |
-3.673
|
-9.279
|
-2.24
|
5.088
|
8.898
|
3.562
|
Net margin
|
-49.25%
|
-122.6%
|
-12.45%
|
20.05%
|
27.58%
|
10.43%
|
EPS
2 |
-0.0104
|
-0.0116
|
-0.002691
|
0.005396
|
0.007394
|
0.003106
|
Free Cash Flow
1 |
-1.592
|
-2.189
|
-2.022
|
1.465
|
3.871
|
-4.048
|
FCF margin
|
-21.35%
|
-28.93%
|
-11.24%
|
5.77%
|
12%
|
-11.85%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
43.05%
|
61.78%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
28.8%
|
43.5%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/14/18
|
6/21/19
|
6/30/20
|
6/14/21
|
6/29/22
|
6/29/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
1.7
|
2.9
|
-
|
-
|
-
|
Net Cash position
1 |
3.19
|
-
|
-
|
0.81
|
5.75
|
3.94
|
Leverage (Debt/EBITDA)
|
-
|
-0.2151
x
|
-2.956
x
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.59
|
-2.19
|
-2.02
|
1.47
|
3.87
|
-4.05
|
ROE (net income / shareholders' equity)
|
-16.6%
|
-62.1%
|
-20.3%
|
38%
|
43%
|
13.1%
|
ROA (Net income/ Total Assets)
|
-17.4%
|
-20.7%
|
-5.79%
|
5.14%
|
10.3%
|
6.52%
|
Assets
1 |
21.17
|
44.81
|
38.71
|
98.93
|
86.11
|
54.6
|
Book Value Per Share
2 |
0.0100
|
-0
|
-0
|
0.0200
|
0.0200
|
0.0300
|
Cash Flow per Share
2 |
0.0100
|
0
|
0
|
0
|
0.0100
|
0.0100
|
Capex
1 |
0.18
|
0.02
|
0.03
|
0.33
|
0.5
|
5.74
|
Capex / Sales
|
2.43%
|
0.25%
|
0.19%
|
1.3%
|
1.55%
|
16.8%
|
Announcement Date
|
6/14/18
|
6/21/19
|
6/30/20
|
6/14/21
|
6/29/22
|
6/29/23
|
|
1st Jan change
|
Capi.
|
---|
| -7.29% | 139M | | +19.98% | 43.48B | | +20.67% | 22.65B | | +14.56% | 14.73B | | +14.32% | 13.79B | | +44.72% | 12.04B | | -8.37% | 7.08B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +11.90% | 5.47B |
Generic Pharmaceuticals
|